Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

Nemlig det kliniske forsøg Mestinon for ME / CFS

Som en, der kender til virkningen af ME / CFS, forstår du, som vi gør, at der er et presserende behov for at forbedre den kliniske pleje af personer, der lider af denne ødelæggende lidelse.

#MayMomentum handler om at sikre, at forskning i ME / CFS og andre relaterede kroniske, komplicerede sygdomme fører til resultater og livsforandrende behandlinger. Vi håber, at du vil bidrage i dag i anledning af #GivingTuesdayNow og vise verden, at der aldrig har været et vigtigere tidspunkt at bekæmpe ME / CFS på end nu!

Med fokus på behandling har OMF investeret 150.000 USD i at studere personer med ME / CFS, som udviser Preload Failure under en invasiv kardiopulmonal motionstest (iCPET). Jeg har bedt Christopher W. Armstrong, PhD, Science Liaison hos Open Medicine Foundation om at forklare, hvorfor vi er så begejstrede for dette seneste projekt:

“Jeg er dybt taknemmelig for at afsløre det første af to nye kliniske forsøg, der udelukkende fokuserer på behandlingsmuligheder for mennesker med ME / CFS , nemlig det kliniske forsøg Mestinon for ME / CFS.

Dette forsøg udføres af Dr. David Systrom Brigham & Women’s Hospital i forbindelse med Harvard ME / CFS-samarbejdet mellem de Harvard-tilknyttede hospitaler. Dr. Systrom har konstateret, at nogle personer med ME / CFS, som også lider af træthed, har det, der kaldes Preload Failure.

I dette tilfælde menes Preload Failure at stamme fra en ubalance i det autonome nervesystem og resulterer i nedsat fyldning af hjertet i forbindelse med anstrengelse. Det kliniske forsøg vil teste motionsreaktionen på Mestinon hos personer med ME / CFS og Preload Failure.

Tidligere studier har vist forbedring hos patienter i den generelle befolkning med Preload Failure efter behandling med Mestinon. Dr. Systrom har til hensigt at evaluere den kortvarige virkning af Mestinon på det autonome nervesystem og den neurovaskulære kontrol hos personer med ME / CFS, som også har Preload Failure.

Undersøgelse af disse funktioner vil øge vores forståelse af ME / CFS, og dette forsøg kan føre til nye og specifikke behandlingsmuligheder for personer med ME / CFS.”

Dette er kun første fase af denne forskning. Der er fortsat meget arbejde forbundet med at levere behandlinger for ME / CFS og andre kroniske, komplicerede sygdomme. OMF stræber efter at overvinde forskelligheden i finansieringen af vores forskningsområde ved at udnytte vores samfunds passion og talentet og engagementet hos forskere i hele verden for at slå bro over finansieringskløften og opretholde forskningens fremdriften frem mod en egentlig kur.

Vi håber, du vil investere i denne vigtige forskning og blive OMFSustaining Donor  under #MayMomentum? Sustaining Donors har fundet den perfekte måde at investere i videnskabelig forskning på.

Dit faste, månedlige bidrag af en hvilken som helst størrelse giver os mulighed for at skabe fremdrift i laboratoriet ved at sikre uafbrudt finansiering. Overvej at investere i dag i den vitale forskning, der udføres på vores fire OMF-etablerede, samarbejdende forskningscentre.

Tak, og pas på jer selv,

 

 

 

 

Linda Tannenbaum
Open Medicine Foundation

 

Giv til #MayMomentum, og vis verden, at det bør være vigtigt for alle at bekæmpe ME / CFS!

 

Bliv Sustaining donor nu

Foretag en engangsdonation til #MayMomentum i dag!

Besøg #MayMomentum for at få flere oplysninger.

Foretrækker du at bruge Facebook til månedligt eller enkeltbidrag?
Se det her: #MayMomentum Facebook

 


Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo